However, several medical therapies for NAFLD targeting various disease pathways have been developed, including Elafibranor (a dual PPARα/δ agonist), 6-ethylchenodeoxycholic acid (OCA) (a synthetic bile acid and FXR activator), CVC (a dual antagonist of CCR2 and CCR5), SEL (GS-4997) (a selective inhibitor of ASK1)35. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.